SEC Form 4 · accession 0001493152-18-001224
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James C Czirr
Director
Period of report
Jan 25, 2018
Accepted (ET)
Jan 29, 2018 · 9:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 25, 2018 | S | 205,144 | $5.45 | D | 3,160,284 | I | See Footnore |
| Common StockF1 | Jan 26, 2018 | S | 39,300 | $5.35 | D | 3,120,984 | I | See Footnore |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.